The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Controlling escape from angiogenesis inhibitors
Open accessAbstract
Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of chemotherapy and has beneficial effects on multiple advanced cancers, but response is often limited and the disease eventually progresses. Changes in the tumour microenvironment — hypoxia among them — that result from vascular pruning, suppressed angiogenesis and other consequences of VEGF inhibition can promote escape and tumour progression. New therapeutic approaches that target pathways that are involved in the escape mechanisms add the benefits of blocking tumour progression to those of slowing tumour growth by inhibiting angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedLee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedEpithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Metastasis: a question of life or death
Mehlen, P., & Puisieux, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1886 · Cited by 1,863
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Regulation of the Chemokine Receptor CXCR4 by Hypoxia
Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A., Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030267 · Cited by 841
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., Hellström, M., Schomber, T., Peltonen, R., et al. (2008) · Nature · doi:10.1038/nature07083 · Cited by 813
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Self-citationAnti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Kioi, M., Vogel, H., Schultz, G., Hoffman, R. M., Harsh, G. R., & Brown, J. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40283 · Cited by 773
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Self-citation(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00002-x · Cited by 751
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
Grothey, A., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D., Hedrick, E., & Kozloff, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Gjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 593
Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha /ARNT
Zelzer, E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5085 · Cited by 575
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Holland, S. J., Pan, A., Franci, C., Hu, Y., Chang, B., Li, W., Duan, M., Torneros, A., Yu, J., Heckrodt, T. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2997 · Cited by 550
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
Cirri, P., & Chiarugi, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9340-x · Cited by 519
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477
Mechanisms of Motility in Metastasizing Cells
Yilmaz, M., & Christofori, G. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0139 · Cited by 477
Integrins: masters and slaves of endocytic transport
Caswell, P. T., Vadrevu, S., & Norman, J. C. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2799 · Cited by 460
Dickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441
Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Self-citationRini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela-Arispe, M. L., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 356
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1667 · Cited by 345
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
Pezzella, F., Pastorino, U., Tagliabue, E., Andreola, S. A., Sozzi, G., Gasparini, G. M., Menard, S., Gatter, K. C., Harris, A. L., Fox, S. B., et al. (1997) · Europe PMC (PubMed Central) · Cited by 330
DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 318
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L., New, T., Zabski, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B., Finke, J. H., & Cohen, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3278 · Cited by 296
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., & Comis, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6630 · Cited by 294
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4789 · Cited by 293
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., & Cohen, P. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281
Chronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264
Dowlati, A., Gray, R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 263
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
Self-citationLoges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hashizume, H., Falcón, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., & McDonald, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1977 · Cited by 251
Self-citationNarayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17492 · Cited by 243
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
Ye, X., Li, Y., Stawicki, S., Couto, S., Eastham-Anderson, J., Kallop, D., Weimer, R., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 232
Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 225
DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
Li, J.-L., Sainson, R. C. A., Oon, C. E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C., Bowden, E. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1704 · Cited by 224
Crosstalk in Met receptor oncogenesis
Lai, A. Z., Abella, J. V., & Park, M. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.07.002 · Cited by 213
Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion
Muller, P. A. J., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S., van den Berghe, P. V. E., Nixon, C., Karim, S. A., Caswell, P. T., Noll, J. E., et al. (2013) · Oncogene · doi:10.1038/onc.2012.148 · Cited by 192
Endogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191
Lambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, F., Serini, G., & Giraudo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58976 · Cited by 187
He, S., Lamers, G. E., Beenakker, J. M., Cui, C., Ghotra, V. P., Danen, E. H., Meijer, A. H., Spaink, H. P., & Snaar‐Jagalska, B. E. (2012) · The Journal of Pathology · doi:10.1002/path.4013 · Cited by 179
Peña, C., Lathia, C., Shan, M., Escudier, B., & Bukowski, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3343 · Cited by 173
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Macrophage regulation of tumor angiogenesis: Implications for cancer therapy
Squadrito, M. L., & De Palma, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.005 · Cited by 170
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091846 · Cited by 170
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.200918462104c · Cited by 163
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 159
Sennino, B., Falcón, B. L., McCauley, D., Le, T., McCauley, T. G., Kurz, J. C., Haskell, A., Epstein, D. M., & McDonald, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0293 · Cited by 159
Self-citationRole of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Rapisarda, A., & Melillo, G. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.002 · Cited by 154
Osterlund, P. J., Soveri, L.-M., Isoniemi, H., Poussa, T. A., Alanko, T., & Bono, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.2 · Cited by 153
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 144
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Bhargava, P., & Robinson, M. O. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0154-3 · Cited by 141
Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Bagri, A., Berry, L., Gunter, B., Singh, M., Kasman, I. M., Damico, L. A., Xiang, H., Schmidt, M., Fuh, G., Hollister, B. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3100 · Cited by 140
Burstein, H. J., Chen, Y., Parker, L. M., Savoie, J., Younger, J., Kuter, I., Ryan, P. D., Garber, J. E., Chen, H., Campos, S. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0593 · Cited by 139
O’Connor, J. P. B., Rose, C. J., Jackson, A., Watson, Y., Cheung, S., Maders, F., Whitcher, B. J., Roberts, C., Buonaccorsi, G. A., Thompson, G., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.191 · Cited by 136
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
Kuhnert, F., Kirshner, J. R., & Thurston, G. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-20 · Cited by 134
Macedo, L. T., Lima, A. B. C., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126
Shojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 122
A preclinical and clinical review of aflibercept for the management of cancer
Gaya, A. M., & Tse, V. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.008 · Cited by 119
Nikolinakos, P. G., Altorki, N. K., Yankelevitz, D. F., Tran, H. T., Yan, S., Rajagopalan, D., Bordogna, W., Ottesen, L. H., & Heymach, J. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2533 · Cited by 118
Hashimoto, K., Man, S., Xu, P., Cruz‐Muñoz, W., Tang, T., Kumar, R., & Kerbel, R. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0960 · Cited by 112
Hussain, M., Smith, M. R., Sweeney, C. J., Corn, P. G., Elfiky, A. A., Gordon, M. S., Haas, N. B., Harzstark, A. L., Kurzrock, R., Lara, P. N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4516 · Cited by 111
Ronzoni, M., Manzoni, M., Mariucci, S., Loupakis, F., Brugnatelli, S., Bencardino, K. B., Rovati, B., Tinelli, C., Falcone, A., Villa, E., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq261 · Cited by 108
Harris, R. J., Cloughesy, T. F., Pope, W. B., Nghiemphu, P. L., Lai, A., Zaw, T., Czernin, J., Phelps, M. E., Chen, W., & Ellingson, B. M. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos141 · Cited by 106
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
Arrondeau, J., Mir, O., Boudou, P., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9764-8 · Cited by 106
Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9526-z · Cited by 103
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0742-t · Cited by 103
Nakahara, T., Norberg, S. M., Shalinsky, D. R., Hu‐Lowe, D. D., & McDonald, D. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0923 · Cited by 102
Self-citationImpact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Jubb, A. M., Miller, K. D., Rugo, H. S., Harris, A. L., Chen, D., Reimann, J. D., Cobleigh, M., Schmidt, M., Langmuir, V. K., Hillan, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1791 · Cited by 101
Willett, C. G., Kozin, S. V., Duda, D. G., di Tomaso, E., Kozak, K. R., Boucher, Y., & Jain, R. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.007 · Cited by 100
Chiu, C. W., Nozawa, H., & Hanahan, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0198 · Cited by 98
Falcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 95
Self-citationCarbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1185 · Cited by 95
Casazza, A., Kigel, B., Maione, F., Capparuccia, L., Kessler, O., Giraudo, E., Mazzone, M., Neufeld, G., & Tamagnone, L. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100205 · Cited by 94
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Zhou, Q. S., & Gallo, J. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-088 · Cited by 91
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas
Tseng, D., Vasquez-Medrano, D. A., & Brown, J. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.169 · Cited by 90
Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Kömüves, L. G., Peale, F. V., Jr., & Ferrara, N. (2012) · The Journal of Pathology · doi:10.1002/path.4052 · Cited by 88
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
Strickler, J. H., & Hurwitz, H. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0003 · Cited by 87
Grépin, R., Guyot, M., Jacquin, M., Durivault, J., Chamorey, E., Sudaka, A., Serdjebi, C., Lacarelle, B., Scoazec, J., Négrier, S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.360 · Cited by 85
Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy
Sitohy, B., Nagy, J. A., Jaminet, S.-C. S., & Dvorak, H. F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1693 · Cited by 82
Cacheux, W., Boisserie, T., Staudacher, L., Vignaux, O., Dousset, B. E., Soubrane, O., Terris, B., Mateus, C., Chaussade, S., & Goldwasser, F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn540 · Cited by 79
Alessi, P., Leali, D., Camozzi, M., Cantelmo, A. R., Albini, A., & Presta, M. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0175 · Cited by 76
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 75
Kawai, N., Maeda, Y., Kudomi, N., Miyake, K., Okada, M., Yamamoto, Y., Nishiyama, Y., & Tamiya, T. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1645-4 · Cited by 72
Dingemans, A. C., de Langen, A. J., van den Boogaart, V., Marcus, J. T., Backes, W. H., Scholtens, H., van Tinteren, H., Hoekstra, O. S., Pruim, J., Brans, B. T., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq391 · Cited by 72
Enhancement of radiation response with bevacizumab
HOANG, T. N., Huang, S., Armstrong, E. A., Eickhoff, J. C., & Harari, P. M. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-37 · Cited by 71
Sapra, P., Kraft, P., Pastorino, F., Ribatti, D., Dumble, M., Mehlig, M., Wang, M., Ponzoni, M., Greenberger, L. M., & Horak, I. D. (2011) · Angiogenesis · doi:10.1007/s10456-011-9209-1 · Cited by 70
Kandel (1992) · International Journal of Oncology · doi:10.3892/ijo_00000131 · Cited by 70
Reappraising antiangiogenic therapy for breast cancer
Kerbel, R. S. (2011) · The Breast · doi:10.1016/s0960-9776(11)70295-8 · Cited by 65
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Shojaei, F., Simmons, B. H., Lee, J. H., Lappin, P. B., & Christensen, J. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.026 · Cited by 63
Turley, R. S., Fontanella, A. N., Padussis, J. C., Toshimitsu, H., Tokuhisa, Y., Cho, E. H., Hanna, G., Beasley, G. M., Augustine, C. K., Dewhirst, M. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3000 · Cited by 59
Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Bagley, R. G., Ren, Y., Weber, W. D., Yao, M., Kurtzberg, L. S., Pinckney, J., Bangari, D. S., Nguyen, C., Brondyk, W. H., Kaplan, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2687 · Cited by 58
In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
Verma, S., McLeod, D., Batist, G., Robidoux, A., Martins, I., & Mackey, J. R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0278 · Cited by 56
Sallinen, H., Anttila, M., Närväinen, J., Koponen, J., Hämäläinen, K. M., Kholová, I., Heikura, T., Toivanen, P. I., Kosma, V., Heinonen, S. T., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.258 · Cited by 51
Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
Duda, D. G., Ancukiewicz, M., & Jain, R. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8021 · Cited by 49
MET and VEGF: synergistic targets in castration-resistant prostate cancer
Aftab, D. T., & McDonald, D. M. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0719-5 · Cited by 48
Self-citationRugo, H. S., Chien, A. J., Franco, S. X., Stopeck, A., Glencer, A., Lahiri, S., Arbushites, M. C., Scott, J. H., Park, J. W., Hudis, C. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1918-z · Cited by 48
Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Zhang, Q., Bindokas, V. P., Shen, J., Fan, H., Hoffman, R. M., & Xing, H. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0008 · Cited by 47
Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Zhong, H. A., & Bowen, J. P. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860924 · Cited by 45
Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
Kerbel, R. S. (2007) · Cancer Research and Treatment · doi:10.4143/crt.2007.39.4.150 · Cited by 45
Vangestel, C., de Wiele, C. V., Damme, N. V., Staelens, S. G., Pauwels, P., Reutelingsperger, C. P. M., & Peeters, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092650 · Cited by 45
Li, H., Adachi, Y., Yamamoto, H., Min, Y., Ohashi, H., Ii, M., Arimura, Y., Endo, T., Lee, C., Carbone, D. P., et al. (2011) · Cancer · doi:10.1002/cncr.25893 · Cited by 44
Jones, M., Caswell, P. T., Moran‐Jones, K., Roberts, M. S., Barry, S. T., Gampel, A., Mellor, H., & Norman, J. C. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00898.x · Cited by 44
Saylor, P. J., Escudier, B. J., & Michaelson, M. D. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.01.010 · Cited by 43
Circulating biomarkers of bevacizumab activity in patients with breast cancer
Denduluri, N., Yang, S. X., Berman, A. W., Nguyen, D., Liewehr, D. J., Steinberg, S. M., & Swain, S. M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.1.5337 · Cited by 41
Cartwright, T. H., Yim, Y. M., Yu, E., Chung, H., Halm, M., & Forsyth, M. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.05.005 · Cited by 40
Dewdney, A., Cunningham, D., Barbáchano, Y., & Chau, I. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.152 · Cited by 35
Arao, T., MATSUMOTO, K. Y., Furuta, K., Kudo, K., Kaneda, H., Nagai, T., Sakai, K., Fujita, Y., Tamura, D., Aomatsu, K., et al. (2011) · PubMed · Cited by 34
Usefulness of HIF-1 Imaging for Determining Optimal Timing of Combining Bevacizumab and Radiotherapy
Ou, G., Itasaka, S., Zeng, L., Shibuya, K., Yi, J., Harada, H., & Hiraoka, M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.083 · Cited by 21
The possible role of chemotherapy in antiangiogenic drug resistance
Bocci, G., & Loupakis, F. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.001 · Cited by 19
Lohmann, A. E., & Chia, S. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0181-9 · Cited by 15
Vascular normalization: a real benefit?
Ribatti, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1683-z · Cited by 15
Heath, E. I., Blumenschein, G. R., Cohen, R. B., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1536-1 · Cited by 14
Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?
Wang, W., Ma, J., Jia, W., & Xu, G. (2011) · Cell Biology International · doi:10.1042/cbi20110171 · Cited by 13
Antiangiogenic therapies: is VEGF-A inhibition alone enough?
Gordon, M. S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.5 · Cited by 4
Cited by
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Tumour acidosis: from the passenger to the driver's seat
Corbet, C., & Feron, O. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.77 · Cited by 988
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Metadata
- Authors
- Sennino, B., & McDonald, D. M.
- Venue
- Nature Reviews Cancer
- Published
- 2012-09-24
- Volume
- 12
- Issue
- 10
- Pages
- 699-709
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1978148288
- Cited by
- 264
- References
- 185
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.